Glycosylphosphatidylinositol specific phospholipase d proteins for the treatment or diagnosis of atherosclerosis
OwnerJulian Schofield, Thomas William Rademacherinventors
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of GPI-PLD for the prevention and treatment of conditions characterised by atherosclerosis. In some embodiments, this process may be caused by a failure to produce GPI-PLD, for example type 1 diabetes, or deliver GPI-PLD, such as patients deficient in apolipoprotein-A1, or those patients with autoantibodies to either GPI-PLD or Apo-A1. In other embodiments, the atherosclerotic process may result from a loss in GPI-PLD activity, e.g. where there is a genetic modification of GPI-PLD either affecting its activity or delivery to a target tissue, thereby leading to the atherosclerotic process.
Claims12
Use of GPI-PLD for the preparation of a medicament for the treatment of conditions characterised by atherosclerosis.
Use of a nucleic acid molecule encoding GPI-PLD for the preparation of a medicament for the treatment of conditions characterised by atherosclerosis.
Use of a host cell capable of expressing and secreting GPI-PLD in the preparation of a medicament for the treatment of conditions characterised by atherosclerosis.
The use of any one of the preceding claims, wherein the condition is type 1 diabetes, a condition characterised by ApoA1 deficiency, a cardiovascular disorders such as coronary artery disease (CAD), systemic lupus erythematosis (SLE) or Sjogren's syndrome.
A kit comprising a composition including GPI-PLD for the treatment of conditions characterised by atherosclerosis.
A method of diagnosing a patient who has or at risk of developing a condition characterised by atherosclerosis, the method comprising determining the amount of GPI-PLD and/or GPI-PLD activity in a sample obtained from the patient.
Dependencies are inferred from the claim text.